Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
minocycline · 1 trial · 1 indication
Establish preliminary estimate of minocycline's impact on progression of HD (measured by the change in Total Functional Capacity (TFC) score of Unified Huntington's Disease Rating Scale \[UHDRS\] between baseline \& Month 18), and to assess futility of further study of minocycline. TFC consists of five ordinally scaled items assessing a person's capacity with: 1. occupation 2. financial affairs 3. domestic responsibilities 4. activities of daily living and 5. independent living. Total score ranges from zero (worst) to 13 (best).
| Arm | Type | Description |
|---|---|---|
| Minocycline | EXPERIMENTAL | Minocycline (3:1 randomization) 100 mg capsules taken by mouth twice daily, 200 mg per day total for 18 months treatment duration. |
| Matching placebo | PLACEBO_COMPARATOR | Sugar pill manufactured to mimic minocycline, 1 capsule taken by mouth twice daily for 18 months treatment duration. |
| Name | Type | Description |
|---|---|---|
| minocycline | DRUG | Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (\~ 8 hours apart) |
| Matching placebo | DRUG | Matching placebo 1 capsule twice daily, 18 months treatment duration. |
Inclusion Criteria: * Age 18 years or older * Clinical features of HD and a confirmatory family history of HD; and/or genetically confirmed HD * Independently walking and fully self-sufficient in activities of daily living (eating, dressing, bathing) * Able to take medication (capsules) by mouth E...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Votoplam |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE3 | Valbenazine |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE1 | ALN-HTT02 |
| uniQure N.V. | QURE | 2 | PHASE1 | intra-striatal rAAV5-miHTT |
| Sarepta Therapeutics, Inc. | SRPT | 1 | PHASE1 | SRP-1005 |
Minocycline is an investigational small molecule being studied for the treatment of Huntington Disease. It is a Phase 2 investigational drug, meaning it is still in clinical development and has not been approved for this use. The completed trial enrolled 114 participants.
Minocycline is being developed by Merit Medical Systems, Inc., a company traded on the Nasdaq under the ticker MMSI. The company is conducting clinical research to evaluate the drug for Huntington Disease.
Minocycline is in Phase 2 clinical development for Huntington Disease. The Phase 2 trial has been completed, and the drug remains investigational. It is not FDA approved for this indication.
Minocycline has one completed Phase 2 clinical trial, identified as NCT00277355, titled "Pilot Study of Minocycline in Huntington's Disease." The trial was conducted in the United States and Canada, enrolled 114 participants, and was randomized, double-blind, and placebo-controlled.
Minocycline is the drug name used in the clinical trial for Huntington Disease. The trial does not specify alternative names such as minocycline hydrochloride, so the drug is referred to simply as minocycline in the study context.